Back to News
Market Impact: 0.25
Radiopharm Doses First Patient In Second Cohort Of Phase 1/2a RV-01 Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Radiopharm Theranostics (RADX) dosed the first patient in the second cohort of its Phase 1/2a first-in-human trial of BetaBart (RV-01) in patients with B7-H3-expressing solid tumors. This is an early clinical milestone indicating continued progression of the program, though full safety/efficacy readouts are still pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
RADX0.25
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off